Carmustine | |
系統(IUPAC)名字 | |
1,3bis (2chloroethyl) - 1亞硝基尿素 | |
標識符 | |
化工數據 | |
214.049 g/mol | |
約物動力學的數據 | |
5到28% (口頭) | |
80% | |
15 |
資料來源:http://en.wikipedia.org/wiki/Carmustine
| N,N'-bis(2-chloroethyl)-N-nitroso-urea |
| 154-93-8 |
| L01AD01 |
| CID 2578 |
| APRD00006 |
| 2480 Y |
| U68WG3173Y Y |
| D00254 Y |
| CHEMBL513 Y |
| C5H9Cl2N3O2 |
| 214.049 g/mol |
| eMolecules & PubChem |
| 5 to 28% (oral) |
| 80% |
| Hepatic (CYP1A2-mediated) |
| 15 to 30 minutes |
| D(US) |
| ℞ Prescription only |
| Intravenous, wafer for implant |
Carmustine or BCNU (= "bis-chloronitrosourea") is a mustard gas-related α-chloro-nitrosourea compound used as an alkylating agent in chemotherapy.
Carmustine for injection is marketed under the name BiCNU by Bristol-Myers Squibb.
Uses
It is used in the treatment of several types of brain cancer (including glioma, glioblastoma multiforme, medulloblastoma and astrocytoma), multiple myeloma and lymphoma (Hodgkin's and non-Hodgkin).
Side effects
Male infertility.
Bone marrow may take 6 weeks to recover function following treatment with carmustine. Weekly monitoring of platelet and white blood cell counts are recommended as a basis for patient-specific adjustments to dosage regimens. Bone marrow and pulmonary toxicities are a function of lifetime cumulative dose.
